Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

genedrive inks distribution deal with Sysmex's Asia-Pacific arm

The agreement provides access to another "important and very relevant" global region for genedrive, the company said
Genedrive
Sysmex will be responsible for marketing the CE-marked Genedrive HCV ID Kit

Diagnostics specialist genedrive PLC (LON:GDR) has extended the “commercial reach” of its relationship with Sysmex Corp, inking a distribution deal with the Japanese group’s Asia-Pacific arm.

Under the agreement, Sysmex will be responsible for sales, marketing and customer support for the CE-marked Genedrive HCV ID Kit and platform in the region.

WATCH: 2017 a year of key milestone achievements for Genedrive's diagnostic Hepatitis-C test

The UK company will retain responsibility for product development, quality management and manufacturing the handheld device for detecting Hepatitis C (HCV).

“This agreement provides access to another important and very relevant global region for genedrive encompassing countries with a high HCV burden,” said chief executive David Budd.

READ: Genedrive highlights improved turnover as it releases first full year results since reboot

The latest collaboration will follow the structure of the October 16 accord between the two businesses that covers Europe, the Middle East and Africa.

genedrive said it anticipates “some initial traction” during the 2017/2018 financial year, with a further “ramp up” in 2018/19 when regulatory milestones are met. It added it had retained the rights over the Indian market.

About the company

genedrive describes itself as a molecular diagnostics company. It is developing and commercialising a low cost, rapid, versatile, simple to use and robust “point of need” system that accurately picks up infectious diseases.

The Genedrive platform and its MTB/RIF test for tuberculosis have already launched in India. The HCV test has undergone rigorous and successful testing with researchers in Paris and Nottingham.

The shares were up 2.4% mid-afternoon.

 

View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

scientist looking through a microscope
October 31 2017
As of March, ReNeuron had £53mln in cash equivalents but its market value is not too much above that....
man on a ventilator
January 24 2018
The share price, 280p a year ago, has tracked the progress the firm has made in the clinic with its lead product Traumakine
test tubes
January 22 2018
Under former chief executive Peter George and his successor Shaun Chilton, it has been transformed via a series of well-judged, quickly integrated and, crucially, cash generative acquisitions

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use